Chikungunya Vaccine, Recombinant
Trade name: Vimkunya
VaccineapprovedBreakthrough Therapy FDA
Approved
Feb 14, 2025
Clinical trial activity
5 trials · 3 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
5
Phase 3
3
Phase 4
0
Earliest trial started Apr 18, 2018 (NCT03483961)
Timeline
Indications
Approved for
Studied for
Mechanism of action
- Chikungunya virusImmunity, active
immunity, active - Chikungunya virus
Approval history
- approvedAcceleratedBreakthroughFeb 14, 2025
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07003984 | Phase 3 | Jun 5, 2025 | Bavarian Nordic |
| NCT06007183 | Phase 3 | Aug 30, 2023 | Bavarian Nordic |
| NCT05065983 | Phase 2 | Oct 11, 2021 | Emergent BioSolutions |
| NCT05072080 | Phase 3 | Sep 29, 2021 | Emergent BioSolutions |
| NCT03483961 | Phase 2 | Apr 18, 2018 | PaxVax, Inc. |
Showing 5 of 5 trials
Page 1 / 1
Organizations
Research & Development (3)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Bavarian Nordic | For profit | 2 | 2 | 1 | 2023 |
| Emergent BioSolutions | For profit | 2 | 2 | 2 | 2021 |
| PaxVax, Inc. | For profit | 1 | 1 | 1 | 2018 |
3 organizations
Page 1 / 1